Results 51 to 60 of about 9,359 (237)

Pediatric Obesity: Influence on Drug Dosing and Therapeutics [PDF]

, 2018
Obesity is an ongoing global health concern and has only recently been recognized as a chronic disease of energy homeostasis and fuel partitioning. Obesity afflicts 17% of US children and adolescents.
Ameer, Barbara, PharmD, MBA, BCPS, FCP, Weintraub, Michael, MD   +1 more
core   +1 more source

Long‐acting insulin analogues and the risk of diabetic nephropathy among patients with type 2 diabetes: A population‐based cohort study

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims The risk of diabetic nephropathy among patients with type 2 diabetes (T2D) can be reduced through optimal glycaemic control. It is not known if the pharmacological properties of long‐acting insulin analogues may reduce the risk of diabetic complications compared with neutral protamine Hagedorn (NPH) insulin.
Julia Brillinger, Christopher Filliter, Shahrzad Salmasi, Estefania Zapata‐Bravo, Robert W. Platt, Oriana H. Y. Yu, Kristian B. Filion   +6 more
wiley   +1 more source

Characterisation of insulin analogues therapeutically available to patients [PDF]

, 2018
The structure and function of clinical dosage insulin and its analogues were assessed. This included ‘native insulins’ (human recombinant, bovine, porcine), ‘fast-acting analogues’ (aspart, glulisine, lispro) and ‘slow-acting analogues’ (glargine ...
Adams, Gary G., Alzahrani, Qushmua E., Ballance, Simon, Besong, David T.M., Chayen, Naomi, Gillis, Richard B., Harding, Stephen E., Jiwani, Shahwar I., Kok, M. Samil, Lithgo, Ryan, Meal, Andrew, Morgan, Paul S., Zobel, Hanne   +12 more
core   +5 more sources

Efficacy and safety of switching basal insulin to insulin glargine 300 U/mL in individuals with inadequately controlled type 2 diabetes on advanced insulin therapies: The Toujeo‐Neo T2DM study

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims This real‐world study evaluated the effectiveness and safety of switching basal insulin (BI) to insulin glargine 300 U/mL (Gla‐300) in adults with inadequately controlled type 2 diabetes mellitus (T2DM), previously receiving basal‐supported oral therapy plus prandial insulin (BOTplus) or multiple (≥3) daily injections (MDI) of short ...
Stefan Pscherer, Andreas Fritsche, Helmut Anderten, Katrin Pegelow, Henry Y. Han, Martin Pfohl, Jochen Seufert   +6 more
wiley   +1 more source

Lower risk of hypoglycaemia and greater odds for weight loss with initiation of insulin detemir compared with insulin glargine in Turkish patients with type 2 diabetes mellitus: local results of a multinational observational study [PDF]

, 2014
BACKGROUND: The purpose of this analysis is to evaluate the safety and effectiveness of insulin initiation with once-daily insulin detemir (IDet) or insulin glargine (IGlar) in real-life clinical practice in Turkish patients with type 2 diabetes mellitus
Anne Louise Svendsen, Jiten Vora, Rifat Emral, Taner Damci, Tanzer Balkir   +4 more
core   +1 more source

Effects of age and disease duration on the glycaemic outcomes and safety of insulin glargine 300 U/mL in people with type 2 diabetes in China: A post‐hoc analysis of the INITIATION study

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims To evaluate the glycaemic outcomes and safety of insulin glargine 300 U/mL (Gla‐300) in Chinese people with uncontrolled type 2 diabetes (T2D) by baseline age and disease duration. Materials and Methods INITIATION was a 24‐week, interventional, single‐arm study where adults with T2D (glycated haemoglobin [HbA1c] 7.5%–11.0%) received Gla ...
Liming Chen, Qiu Zhang, Binhong Duan, Xiaohong Wu, Hailong Wan, Binhong Wen, Jie Han, Haixia Liu, Caixian Yang, Weiwei Liu, Qin Du, Lei Kang, Minlu Zhang   +12 more
wiley   +1 more source

Detemir as a once-daily basal insulin in type 2 diabetes

Clinical Pharmacology: Advances and Applications, 2011
Scott E NelsonCleveland Family Medicine, Cleveland, Mississippi, USABackground: Insulin detemir, a long-acting basal insulin analog, is labeled for once-daily or twice-daily dosing in patients with type 1 (T1DM) or type 2 (T2DM) diabetes mellitus ...
Nelson SE
doaj  

A systematic review of glucocorticoid use in type 1 diabetes: Glycaemic effects and clinical management strategies

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Glucocorticoids (GCs) are widely utilised for the treatment of inflammatory and autoimmune conditions but often precipitate significant hyperglycaemia. People with type 1 diabetes (PWT1D) may be particularly affected due to the challenges of adjusting insulin dosing, for which recommendations remain unclear.
Alexandra Katz, Aidan Shulkin, Asmaa Housni, Amélie Roy‐Fleming, Rémi Rabasa‐Lhoret, Jean‐Francois Yale, Michael A. Tsoukas, Tricia M. Peters, Anne‐Sophie Brazeau   +8 more
wiley   +1 more source

The management of type 1 and type 2 diabetes in pregnancy [PDF]

, 2015
Pregestational diabetes is a common medical complication of pregnancy and preconception planning is an essential component of care for affected women of childbearing age.
Dunne, F P, Egan, A M, Murphy, H R
core   +1 more source

Artificial lipidation of proteins and peptides: from mechanism to clinical applications

The FEBS Journal, EarlyView.
Artificial lipidation transforms protein and peptide therapeutics by attaching fatty acid chains through reversible or permanent chemical strategies. This biomimetic approach delivers four key therapeutic advantages: extended circulation times (enabling weekly instead of daily dosing), alternative administration routes including oral delivery, precise ...
Jiaming Mu, Emily Vong, Sheiliza Carmali
wiley   +1 more source